Rituximab is a monoclonal antibody that depletes a specific subset of immune cells called B cells, and it has become one of the most widely used biologic therapies for autoimmune diseases that resist conventional treatment. Originally developed for blood cancers in the late 1990s, it has since proven effective in conditions ranging from rheumatoid arthritis and vasculitis to pemphigus and neuromyelitis optica. The infusion itself, the timeline of immune effects, and the long-term risks are more nuanced than most patients expect going in.
How Rituximab Works
Rituximab targets a protein called CD20, which sits on the surface of B cells. When the drug binds to CD20, it marks those cells for destruction by the rest of the immune system. B cells play several roles in autoimmune disease: they can produce the antibodies that attack your own tissues, they can present fragments of self-proteins to other immune cells and ramp up inflammation, and they release signaling molecules that keep the immune response going. Depleting them interrupts all of these pathways at once, which is part of why rituximab works across such a wide range of conditions.1Kidney International. Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives
The drug does not wipe out all antibody-producing cells. Long-lived plasma cells, which have already matured past the CD20-expressing stage, survive the treatment and continue making protective antibodies against infections you’ve encountered before. This is why most patients retain some baseline immunity even while their B-cell counts are near zero, though the picture gets more complicated with repeated courses.
Evidence in Rheumatoid Arthritis
Rheumatoid arthritis was the condition that brought rituximab into mainstream autoimmune care. A landmark trial published in the New England Journal of Medicine found that patients given rituximab alongside methotrexate were roughly three times more likely to achieve meaningful symptom improvement than those on methotrexate alone. About 43% of the rituximab-plus-methotrexate group hit the threshold for a 50% improvement in symptoms at six months, compared with 13% on methotrexate only, and those responses held at nearly a year.2PubMed. Efficacy of B-Cell-Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis A systematic review of randomized trials later confirmed these findings, reporting that rituximab combined with methotrexate was effective in patients who had already failed other disease-modifying drugs or TNF-blocking biologics.3PubMed. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials
Real-world registry data from the US Corrona Registry paint a practical picture of what patients experience after starting rituximab. At baseline, nearly nine out of ten patients had moderate or high disease activity. One year after their first infusion, about 30% had reached low disease activity or remission. Roughly half achieved clinically meaningful improvements in pain, fatigue, and their own global assessment of how they were doing. Among those who had reported trouble with daily activities like walking or self-care before treatment, a meaningful fraction reported those problems had resolved.4PubMed Central. Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry
Beyond Rheumatoid Arthritis
Rituximab’s reach extends well beyond joints. In systemic vasculitis associated with rheumatoid arthritis, a registry study found that about 70% of patients achieved complete remission of their vasculitis within six months, and that figure climbed to over 80% by a year. Patients who received maintenance rituximab infusions between the six- and twelve-month marks had no relapses.5PubMed. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry
The drug is also used in lupus-associated immune thrombocytopenia, a condition where the immune system destroys platelets. A small trial of low-dose rituximab in patients with this refractory condition found that nearly 90% responded within three months, and three-quarters maintained their response at a year.6PubMed Central. A modified regimen of low-dose rituximab therapy for patients with refractory immune thrombocytopenia associated with systemic lupus erythematosus Case-based reviews have described rituximab as probably the most viable option for children with lupus-related refractory thrombocytopenia when other treatments have failed.7PubMed. Rituximab alleviates pediatric systemic lupus erythematosus associated refractory immune thrombocytopenia: a case-based review Other conditions treated with rituximab include ANCA-associated vasculitis, pemphigus vulgaris, neuromyelitis optica spectrum disorder, and certain kidney diseases like membranous nephropathy.
What Happens During and Around the Infusion
A standard rituximab course for autoimmune disease typically involves two intravenous infusions given two weeks apart, with each dose administered slowly over several hours. The first infusion is usually the longest because the rate is increased gradually to watch for reactions. Before each infusion, you’ll receive premedication, commonly including an antihistamine, acetaminophen, and a corticosteroid to reduce the risk of infusion reactions.8The Journal of Rheumatology. Montelukast as a Rescue and Premedication for Rituximab Infusion Reactions
Infusion reactions are the most common side effect. Most are mild to moderate and happen during or shortly after the first infusion: flushing, chills, throat tightness, drops in blood pressure, or a rash. The infusion nurse will slow or pause the drip if symptoms appear, and they usually resolve quickly. Severe cytokine release syndrome, where the body mounts an overwhelming inflammatory response, has been reported but is very rare in the autoimmune setting and is much more associated with patients who have high tumor burden from blood cancers.9PubMed Central. Rituximab and cytokine release syndrome A pediatric retrospective study found infusion-related events in about 32% of patients, mostly mild symptoms like chest tightness, fever, and headache, with severe anaphylaxis being uncommon.10PubMed Central. The indications and safety of rituximab for the treatment of pediatric autoimmune diseases: a single-center retrospective study
How Long B-Cell Depletion Lasts
After a course of rituximab, B cells typically drop to near-undetectable levels within a few weeks. How long they stay depleted varies enormously from person to person. In a study of patients with multiple sclerosis treated with extended rituximab dosing intervals, the median time for total B-cell counts to return to the lower end of normal was about 12 months, and memory B cells took around 16 months.11PubMed Central. Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis A longitudinal study across multiple autoimmune diseases confirmed that the trajectory of B-cell return is heterogeneous, with a specific cluster of patients showing prolonged depletion lasting well beyond what is typical.12PubMed. B cell repopulation trajectory after rituximab treatment in autoimmune diseases: a longitudinal observational study
Age at treatment appears to matter. A pediatric study found that younger children were more likely to repopulate their B cells early, while older children and those who had received more infusions tended toward later repopulation.13PubMed. Factors Influencing Early and Late B-Cell Repopulation After Rituximab Therapy in Pediatric Central Nervous System Inflammatory Disorders For clinicians, this variability means that retreatment schedules often need to be individualized rather than set on a rigid calendar. Some patients maintain disease control for many months after B cells start coming back, while others flare as soon as repopulation begins.
Using B-Cell Counts to Predict Relapse
Researchers are working on using the pattern of B-cell return to anticipate when a patient is likely to relapse. In membranous nephropathy, a kidney disease, investigators found that patients who relapsed had significantly higher proportions of certain B-cell subtypes at six months after rituximab compared to those who stayed in remission. The differences were striking: total B cells, naïve B cells, and a subset expressing the CD38 marker were all substantially higher in relapsing patients. The researchers identified specific thresholds for each cell type, and patients who exceeded them faced a significantly higher risk of relapse within 18 months.14Kidney International Reports. Early-Stage B-cells Predict Relapse After Rituximab Treatment in Patients With Membranous Nephropathy The implication is that routine monitoring of B-cell subsets, rather than just total B-cell counts, could help doctors decide when to retreat before a flare actually happens.
Infection Risks Over Time
The most discussed long-term risk of repeated rituximab is a gradual decline in immunoglobulin levels, particularly IgG, the antibody class most important for fighting infections. A large study found that about one in five patients who started with normal IgG levels before rituximab developed low levels afterward. Among those who already had mildly low IgG before treatment, roughly a quarter progressed to moderate or severe deficiency.15JAMA Network Open. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia
The decline is not necessarily immediate. A 14-year real-world study of patients with neuromyelitis optica spectrum disorder found that average IgG levels began falling significantly after two years of rituximab and continued declining at a rate of roughly 2% to 8% per year for the following eight years before leveling off. The proportion of patients with low IgG rose from about 1% after one year of treatment to 41% after 14 years.16PubMed Central. Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders: A 14-Year Real-Life Experience This is why many doctors monitor immunoglobulin levels periodically in patients on long-term rituximab, and some patients eventually need immunoglobulin replacement therapy.
Hepatitis B and Other Viral Reactivations
The most dangerous specific infection risk is hepatitis B reactivation. Even in patients who appear to have cleared a past hepatitis B infection, rituximab can allow the virus to resurge, sometimes leading to fulminant liver failure. The FDA issued a warning in 2013 requiring screening for hepatitis B before starting rituximab.17Clinical Kidney Journal. Infectious complications of rituximab therapy in renal disease The American Gastroenterological Association classified rituximab as a high-risk agent for reactivation, though this assessment was based mostly on data from blood cancer patients receiving rituximab alongside other chemotherapy. The risk appears lower, though not absent, when rituximab is used for autoimmune conditions.18Seminars in Hematology. Rituximab-Associated Infections
Progressive multifocal leukoencephalopathy, or PML, is a rare but often fatal brain infection caused by the JC polyomavirus. By 2011, over a hundred cases of PML had been reported in patients receiving rituximab, though the vast majority were in people with lymphoma who were also on other immunosuppressive drugs. A handful of cases occurred in patients with rheumatoid arthritis or lupus. The absolute risk is considered very low, but patients should be aware of the possibility and report new neurological symptoms promptly.19Clinical Kidney Journal. Infectious complications of rituximab therapy in renal disease
Vaccines and Rituximab
If you’re on rituximab, your ability to respond to vaccines is reduced, sometimes substantially. In a study of patients with immune thrombocytopenia, only about one in five rituximab-treated patients mounted a strong antibody response to pneumococcal vaccine, compared with two-thirds of those on placebo. Responses to Haemophilus influenzae type b vaccine were similarly blunted. Some rituximab-treated patients failed to respond to any vaccine tested, and the impairment lasted at least six months after treatment.20PubMed Central. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia
The picture is a bit more nuanced for recall antigens, meaning vaccines that boost immunity you already have. One study found that tetanus/diphtheria and hepatitis A vaccine responses were still protective in rituximab-treated patients when given after B cells had started recovering, though the responses were weaker than in controls. Responses to a brand-new antigen the immune system had never seen before were severely reduced during full B-cell depletion, but recovered once B cells returned.21Journal of Allergy and Clinical Immunology. Effect of rituximab on human in vivo antibody immune responses An earlier study confirmed that rituximab impaired the secondary immune response to recall antigens and noted that even before treatment, the study patients were unable to respond to primary antigens, suggesting their underlying disease already compromised immune function.22Blood. Rituximab treatment results in impaired secondary humoral immune responsiveness
The practical takeaway: if you know you’re going to start rituximab, get any needed vaccinations beforehand. If you’re already on it, the best window for vaccination is when B cells have started to recover but before your next scheduled course. Live vaccines are generally avoided while B cells are depleted.
Rituximab in Children
Pediatric use of rituximab for autoimmune disease has grown steadily, though most of it remains off-label. A study of 104 children, half of them with lupus, found that rituximab was safely administered and contributed to decreased disease activity and reduced steroid burden. The rate of serious infections was similar to what has been reported in pediatric lupus patients generally.23PubMed. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases The most commonly used pediatric protocol involves two infusions of 375 mg per square meter of body surface area, given two weeks apart.24PubMed Central. The indications and safety of rituximab for the treatment of pediatric autoimmune diseases: a single-center retrospective study Children tend to repopulate B cells faster than adults, which can mean more frequent dosing but also potentially less cumulative immunosuppression over a given timeframe.
Pregnancy Considerations
Rituximab crosses the placenta, which raises theoretical concerns about the fetus’s developing immune system. A case series of pregnancies where the mother had received rituximab either before or during pregnancy found no serious or opportunistic infections in any of the infants and no cases of B-cell depletion in the newborns.25PubMed Central. Pregnancy outcomes following maternal treatment with rituximab prior to or during pregnancy: a case series This is somewhat reassuring, but case series are small by nature, and most guidelines still recommend completing rituximab treatment well before a planned pregnancy. The general advice from rheumatology societies is to allow at least six months between the last rituximab dose and conception, though some specialists are comfortable with shorter intervals depending on the clinical situation.
The Subcutaneous Alternative
For oncology indications, a subcutaneous formulation of rituximab combined with hyaluronidase has been approved. The injection takes only about five to eight minutes instead of the hours required for intravenous infusion, and clinical data have shown comparable efficacy and similar side-effect profiles.26PubMed Central. Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma27British Journal of Cancer. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase A time-and-motion study across eight countries found that the subcutaneous route cut chair time by about 74%, from an average of roughly 262 minutes to 67 minutes.28PLoS ONE. Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
As of now, the subcutaneous formulation is approved only for certain lymphomas and leukemias, not for autoimmune indications. Some autoimmune patients are aware of the subcutaneous option from oncology and ask about it, but formal regulatory approval and dosing studies for autoimmune diseases are still pending. A newer anti-CD20 antibody called ofatumumab, which was engineered for subcutaneous self-injection, has been approved for relapsing multiple sclerosis and represents a shift toward more convenient dosing in the autoimmune space.29SpringerLink (Neurology and Therapy). The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
Biosimilars and Cost
The original rituximab (MabThera/Rituxan) is now off patent, and several biosimilars are available. Clinical trials have consistently shown that these biosimilars are therapeutically equivalent. In rheumatoid arthritis, a three-arm randomized trial found that a biosimilar produced comparable B-cell depletion, disease activity improvements, safety profiles, and immunogenicity to the reference product.30PubMed Central. Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis Another randomized study established clinical equivalence between a different biosimilar and the reference product in rheumatoid arthritis, with no safety differences observed even when patients were switched mid-treatment.31PubMed Central. Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis In pemphigus, a comparative study of 124 patients found no significant differences in time to complete remission or steroid use between biosimilar and originator rituximab.32PubMed Central. Comparative study of efficacy and safety: Biosimilar rituximab versus originator rituximab in the treatment of pemphigus
The cost implications are meaningful. A systematic review and meta-analysis of cost-effectiveness studies found rituximab to be significantly cost-effective for rheumatoid arthritis from a health system perspective.33PubMed. Cost Effectiveness of Rituximab Therapy for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cost-Utility Studies For pemphigus vulgaris, a cost-utility analysis found that first-line biosimilar rituximab was both more effective and less costly than mycophenolate mofetil, the main alternative.34JAMA Dermatology. Cost-Utility Analysis of Rituximab vs Mycophenolate Mofetil for the Treatment of Pemphigus Vulgaris Biosimilar availability has made rituximab more accessible in countries where the originator’s price was a barrier, and for many payers, it has shifted rituximab from a cost concern to a cost advantage compared with other biologics in the same therapeutic space.
What Patients Wish They Had Known
A few practical points tend to catch people off guard. First, rituximab does not work fast in the way that a steroid burst does. It can take weeks to months after an infusion before you notice improvement, because the downstream effects of removing B cells unfold gradually. Second, you will likely need lab work before each course and at intervals in between, including B-cell counts, immunoglobulin levels, and hepatitis B screening. Third, the timing of your infusion relative to other treatments matters. If you’re also on methotrexate or another immunosuppressive drug, your doctor has likely calculated the dosing schedule to maximize efficacy without compounding infection risk too much.
Fourth, the fatigue that some patients experience in the days following an infusion is real and underappreciated. Premedication with corticosteroids can also cause temporary insomnia or mood changes. Planning the infusion for a day when you can rest the next day is worth considering. Fifth, dental health deserves attention: with reduced antibody levels over time, the risk of infections in general goes up, and dental infections are among the more common ones that patients report. Staying current on dental care is a small thing that can prevent a complicated problem down the line.